Rationale and Design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study): A phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cell vs. Allogeneic Mesenchymal Stem Cells in Patients with Non-ischemic Dilated Cardiomyopathy

Journal of Cardiovascular Translational Research

Volumn 7, Issue 9, 2014, Pages 769-780

  Mushtaq, Muzammil ^a   DiFede, Darcy L ^a   Golpanian, Samuel ^a   Khan, Aisha ^a   Gomes, Samirah A ^a   Mendizabal, Adam ^b   Heldman, Alan W ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

Bone marrow cells; Dilated cardiomyopathy; Heart failure; Stem cells

Indexed keywords

ALLOGENEIC MESENCHYMAL STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENDOCARDIAL INJECTION CATHETER; HEART MUSCLE BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MESENCHYMAL STEM CELL TRANSPLANTATION; NONISCHEMIC CARDIOMYOPATHY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BIOPSY; CARDIOMYOPATHY, DILATED; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOLOGY; ENDOCARDIUM; INJECTION; PROCEDURES; TRANSPLANTATION;

BIOPSY; CARDIOMYOPATHY, DILATED; ENDOCARDIUM; HUMANS; INJECTIONS; MESENCHYMAL STEM CELL TRANSPLANTATION; PILOT PROJECTS; TISSUE AND ORGAN HARVESTING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84911484401     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-014-9594-0     Document Type: Article

References (35)

1. Hare, J. M. (2011). The dilated, restrictive and infiltrative cardiomyopathies. In R. O. M. D. L. Bonow, D. P. Zipes, & P. Libby (Eds.), Braunwald’s Heart Disease: a textbook of cardiovascular medicine. Philadelphia: Saunders Elsevier.
2. Hare, J. M., Walford, G. D., Hruban, R. H., Hutchins, G. M., Deckers, J. W., & Baughman, K. L. (1992). Ischemic cardiomyopathy: endomyocardial biopsy and ventriculographic evaluation of patients with congestive heart failure, dilated cardiomyopathy and coronary artery disease. Journal of the American College of Cardiology, 20, 1318–1325.
3. Hare, J. M., Traverse, J. H., Henry, T. D., Dib, N., Strumpf, R. K., Schulman, S. P., et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54, 2277–2286.
4. Heldman, A. W., DiFede, D. L., Fishman, J. E., Zambrano, J. P., Trachtenberg, B. H., Karantalis, V., et al. (2014). Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA, 311, 62–73.
5. Yousef, M., Schannwell, C. M., Kostering, M., Zeus, T., Brehm, M., & Strauer, B. E. (2009). The balance study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. Journal of the American College of Cardiology, 53, 2262–2269.
6. Vrtovec, B., Poglajen, G., Lezaic, L., Sever, M., Domanovic, D., Cernelc, P., et al. (2013). Effects of intracoronary cd34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circulation Research, 112, 165–173.
7. Hare, J. M., Fishman, J. E., Gerstenblith, G., DiFede Velazquez, D. L., Zambrano, J. P., Suncion, V. Y., et al. (2012). Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA, 308, 2369–2379.
8. Da Silva, J. S., & Hare, J. M. (2013). Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart. Methods in Molecular Biology, 1037, 145–163.
9. Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., et al. (2012). Third universal definition of myocardial infarction. Journal of the American College of Cardiology, 60, 1581–1598.
10. Sasaki, T., Miller, C. F., Hansford, R., Zipunnikov, V., Zviman, M. M., Marine, J. E., et al. (2013). Impact of nonischemic scar features on local ventricular electrograms and scar-related ventricular tachycardia circuits in patients with nonischemic cardiomyopathy. Circulatory Arrhythmia Electrophysiol, 6, 1139–1147.
11. D’Amario, D., Fiorini, C., Campbell, P. M., Goichberg, P., Sanada, F., Zheng, H., et al. (2011). Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. Circulation Research, 108, 857–861.
12. Bolli, R., Chugh, A. R., D’Amario, D., Loughran, J. H., Stoddard, M. F., Ikram, S., et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (scipio): initial results of a randomised phase 1 trial. Lancet, 378, 1847–1857.
13. Heidecker, B., Lamirault, G., Kasper, E. K., Wittstein, I. S., Champion, H. C., Breton, E., et al. (2010). The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. European Heart Journal, 31, 1188–1196.
14. Amado, L. C., Saliaris, A. P., Schuleri, K. H., St John, M., Xie, J. S., Cattaneo, S., et al. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 102, 11474–11479.
15. Amado, L. C., Schuleri, K. H., Saliaris, A. P., Boyle, A. J., Helm, R., Oskouei, B., et al. (2006). Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. Journal of the American College of Cardiology, 48, 2116–2124.
16. Parakh, K., Kittleson, M. M., Heidecker, B., Wittstein, I. S., Judge, D. P., Champion, H. C., et al. (2012). The variable natural history of idiopathic dilated cardiomyopathy. Israel Medical Association Journal: IMAJ, 14, 666–671.
17. Hare, J. M. (2008). The etiologic basis of congestive heart failure. In W. S. Colucci (Ed.), Atlas of Heart Failure (pp. 29–56). Philadelphia: Springer.
18. Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine, 355, 251–259.
19. Levy, W. C., Mozaffarian, D., Linker, D. T., Sutradhar, S. C., Anker, S. D., Cropp, A. B., et al. (2006). The Seattle heart failure model: prediction of survival in heart failure. Circulation, 113, 1424–1433.
20. Heidecker, B., Kasper, E. K., Wittstein, I. S., Champion, H. C., Breton, E., Russell, S. D., et al. (2008). Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation, 118, 238–246.
21. Heidecker, B., Kittleson, M. M., Kasper, E. K., Wittstein, I. S., Champion, H. C., Russell, S. D., et al. (2011). Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation, 123, 1174–1184.
22. Martino, H. F., Oliveira, P. S., Souza, F. C., Costa, P. C., Assuncao, E. S. E., Villela, R., et al. (2010). A safety and feasibility study of cell therapy in dilated cardiomyopathy. Brazilian Journal of Medical and Biological Research, 43, 989–995.
23. Freyman, T., Polin, G., Osman, H., Crary, J., Lu, M., Cheng, L., et al. (2006). A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. European Heart Journal, 27, 1114–1122.
24. Perin, E. C., Silva, G. V., Assad, J. A., Vela, D., Buja, L. M., Sousa, A. L., et al. (2008). Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 44, 486–495.
25. Perin, E. C., Silva, G. V., Fernandes, M. R., Munger, T., Pandey, A., Sehra, R., et al. (2007). First experience with remote left ventricular mapping and transendocardial cell injection with a novel integrated magnetic navigation-guided electromechanical mapping system. EuroIntervention: Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 3, 142–148.
26. Mathiasen, A. B., Jorgensen, E., Qayyum, A. A., Haack-Sorensen, M., Ekblond, A., & Kastrup, J. (2012). Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells in chronic ischemic heart failure (MSC-HF trial). American Heart Journal, 164, 285–291.
27. Duran, J. M., Taghavi, S., Berretta, R. M., Makarewich, C. A., Sharp Iii, T., Starosta, T., et al. (2012). A characterization and targeting of the infarct border zone in a swine model of myocardial infarction. Clinical and Translational Science, 5, 416–421.
28. Kharlamov, A. N., Duckers, H. J., van Beusekom, H. M., Smits, P. C., Perin, E. C., & Serruys, P. W. (2013). Do we have a future with transcatheter adventitial delivery of stem cells? International Journal of Cardiology, 165, 217–221.
29. Dib, N., Dinsmore, J., Lababidi, Z., White, B., Moravec, S., Campbell, A., et al. (2009). One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). Journal of the American College of Cardiology: Cardiovascular Interventions, 2, 9–16.
30. Smits, P. C., Nienaber, C., Colombo, A., Ince, H., Carlino, M., Theuns, D. A., et al. (2006). Myocardial repair by percutaneous cell transplantation of autologous skeletal myoblast as a standalone procedure in post myocardial infarction chronic heart failure patients. EuroIntervention: Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 1, 417–424.
31. Smits, P. C., van Geuns, R. J., Poldermans, D., Bountioukos, M., Onderwater, E. E., Lee, C. H., et al. (2003). Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. Journal of the American College of Cardiology, 42, 2063–2069.
32. Williams, A. R., & Hare, J. M. (2011). Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation Research, 109, 923–940.
33. Quevedo, H. C., Hatzistergos, K. E., Oskouei, B. N., Feigenbaum, G. S., Rodriguez, J. E., Valdes, D., et al. (2009). Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences of the United States of America, 106, 14022–14027.
34. Singla DK, Abdelli LS. (2014). Embryonic stem cells and released factors stimulate c-kit/flk-1 progenitor cells and promote neovascularization in doxorubicin-induced cardiomyopathy. Cell Transplant.
35. Rupp, S., Bauer, J., von Gerlach, S., Fichtlscherer, S., Zeiher, A. M., Dimmeler, S., et al. (2012). Pressure overload leads to an increase of cardiac resident stem cells. Basic Research in Cardiology, 107, 252.